• About
  • Team
  • Products
  • Partners
  • Press
  • Clinical Papers
  • Contact
  • Senior Management, Chairman cum Acting CEO

    Yoh-Chie Lu, MBA

    40 years of experience in the biomedical industry.

    Served as President for Medical Division of Gould and British Oxygen in Tokyo and took the company to IPO through leverage buyout in Nasdaq.

    Founder & CEO of Biosensors International Group (柏盛国际). Parent company of JWMS.

    Member of National Research Foundation since 2016.

    Lecturer at both Stanford University Biodesign in USA and invited speaker to NUS & NTU.

    Limited & Venture Partner of Vertex Healthcare Singapore.

  • Senior Management, Chief Technology Officer

    Dr. Solomon Su, PhD

    Team leader at Biosensors (柏盛国际) for technology transfer including Biolimus drug and device from USA to Singapore.

    20 years of experience in the biomedical and pharmaceutical industry as a technical leader with successful track record of take products from R&D to commercial.

    Inventor / co-inventor of multiple worldwide patents.

  • Senior Management, Director of Finance & BD

    Christopher Lee

    Professional manager with decades of diverse business development experience across Asia in medtech, medical aesthetic, food manufacturing and franchise operations.

    Experience in IPO process (Biosensors 柏盛国际) , startups fundraising and operations.

    Inventor / co-inventor of multiple worldwide patents.

  • Board of Directors, Co-Founder

    Tina Wong, MBBS, FRCOphth, FRCSEd, PhD

    Head and Senior Consultant Ophthalmologist of the Glaucoma Service at the Singapore National Eye Centre;

    Director and Head of the Ocular Therapeutics and Drug Delivery Research Group at the Singapore Eye Research Institute; published over 200 scientific papers and delivered numerous presentations as invited speaker at international conferences, academic institutes and universities.

  • Board of Directors, Co-Founder

    Fauad Hasan, MS, MBA

    Co-Founder, President and CEO of Bonti, which was acquired by Allergan (NASDAQ:AGN) in October 2018 for the upfront payment of $195 million and significant subsequent milestone payments;

    Served at Allergan in various leadership roles, including Global Product Development teams of top tier neurotoxin, CMO management and ocular programs.

    More than 20 years of experience in various leadership roles in the Biopharmaceutical industry.

  • Board Of Advisers

    Steve Yoelin, M.D

    Ophthalmologist based in California

    Highly experienced injector, clinical researcher & thought leader in medical facial aesthetic field.

    Highly experienced PI in clinical trials including LATISSE for Allergan.

    Current adviser to Allergan, Galderma and The Beauty Company.

  • Board Of Advisers

    Yehid Hashad MD

    SVP and Head of multiple R&D and clinical trials positions at Abbvie, Allergan and Novartis.

    Highly experienced in drug development and clinical trials process.

  • Board Of Advisers

    Frank Fazio

    Highly experienced clinical trial researcher.

    Multiple positions in Allergan, INAMED and ZoSkin Health

'Putting the Science into Sight'

  • About Us
  • The Team
  • Products
  • Contact Us